Nuvalent Appoints Ron Squarer to Board of Directors

Core Insights - Nuvalent, Inc. has appointed Ron Squarer to its Board of Directors, enhancing its leadership in oncology therapeutics [1][2] - Squarer brings over 30 years of experience in oncology drug development and commercialization, having held significant roles in various pharmaceutical companies [2][3] - The company is preparing for the potential approval and launch of zidesamtinib for TKI pre-treated ROS1-positive non-small cell lung cancer in 2026 [2][3] Company Overview - Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on developing precisely targeted therapies for cancer, specifically targeting clinically proven kinase targets [4] - The company utilizes expertise in chemistry and structure-based drug design to create innovative small molecules aimed at overcoming resistance and minimizing adverse events [4] - Nuvalent is advancing a robust pipeline that includes investigational candidates for ROS1-positive, ALK-positive, and HER2-altered non-small cell lung cancer, along with multiple discovery-stage research programs [4]